Table 1.
Situation | Strategies | Ref. |
---|---|---|
BRAF fusion | pan-RAF inhibitors | (75) |
BRAF inhibitors and RAF inhibitors | (76, 77) | |
combination of MEK inhibitors and EGFR inhibitors | (25, 77) | |
Acquired drug resistance to vemurafenib | intermittent dosing | (78–80) |
Changes in multiple key tumorigenesis pathways and mechanisms | low toxicity “broad-spectrum” treatment | (81) |
Resistant mutations at different gene target | different drug combinations | (82) |